重症期间强化肠内蛋白质:TARGET Protein随机临床试验
该集群随机交叉开放标签试验在澳大利亚和新西兰8个ICU纳入3397例接受肠内营养的危重患者,比较强化蛋白质配方(100 g蛋白质/L)与常规蛋白质配方(63 g蛋白质/L)。主要终点90天无指数医院住院且存活天数中位数强化组62天 vs 常规组64天,调整周期后组间中位差-1.97天(95%CI -7.24至3.30,P=0.46)。90天存活率强化组72.6%(1221/1681)vs 常规组74.0%(1269/1716),风险比0.99(95%CI 0.95-1.03)。次要终点包括存活者无住院天数、有创通气时长、ICU及住院时长、气管造口和新肾脏替代治疗发生率等组间均无显著差异。结论:重症期间强化肠内蛋白质未改善90天无指数医院住院且存活天数。
要点
- 重症期间强化肠内蛋白质(100 g/L)vs 常规蛋白质(63 g/L),90天无指数医院住院且存活天数中位差-1.97天(95%CI -7.24至3.30,P=0.46)。
- 90天存活率强化组72.6%(1221/1681)vs 常规组74.0%(1269/1716),风险比0.99(95%CI 0.95-1.03)。
- 存活者90天无指数医院住院天数中位差0.01天(95%CI -1.94至1.96),有创通气时长均值差6.8小时(95%CI -3.0至16.5)。
- ICU住院时长cause-specific HR 0.93(95%CI 0.88-1.00),住院时长HR 0.96(95%CI 0.90-1.02),气管造口RR 1.15(95%CI 0.66-2.01),新肾脏替代治疗RR 0.97(95%CI 0.81-1.16)。
- 出院去向组间相似。
适用人群与场景
- 澳大利亚和新西兰8个ICU中接受肠内营养的危重患者,共3397例(中位年龄61岁,IQR 48-71;男性2157例,64%)。
处置流程与药物剂量
- 比较两种等热量肠内配方:强化蛋白质(100 g蛋白质/L)vs 常规蛋白质(63 g蛋白质/L)。
- 各ICU在12个月期间按3个月顺序使用两种配方;4个ICU起始使用强化蛋白质,4个起始使用常规蛋白质。
研究设计与关键结果
- 集群随机、交叉、开放标签试验,纳入3397例危重患者,比较强化肠内蛋白质(100 g/L)与常规蛋白质(63 g/L)。
- 主要终点90天无指数医院住院且存活天数中位数:强化组62天(IQR 0-77)vs 常规组64天(IQR 0-77),调整周期后组间中位差-1.97天(95%CI -7.24至3.30,P=0.46)。
- 90天存活:强化组1221/1681(72.6%)vs 常规组1269/1716(74.0%),风险比0.99(95%CI 0.95-1.03)。
- 存活者90天无指数医院住院天数中位差0.01天(95%CI -1.94至1.96);有创通气时长均值差6.8小时(95%CI -3.0至16.5)。
- ICU住院时长cause-specific HR 0.93(95%CI 0.88-1.00);住院时长cause-specific HR 0.96(95%CI 0.90-1.02);气管造口RR 1.15(95%CI 0.66-2.01);新肾脏替代治疗RR 0.97(95%CI 0.81-1.16);出院去向相似。
证据类型、等级与局限
- 证据类型:集群随机交叉开放标签临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:重症期间强化肠内蛋白质未改善90天无指数医院住院且存活天数。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Guidelines recommend augmenting enteral protein during critical illness, but the impact on patient outcomes is uncertain.
OBJECTIVE: To determine whether augmenting enteral protein increases days alive and free from hospitalization.
DESIGN, SETTING, AND PARTICIPANTS: This cluster randomized, crossover, open-label trial recruited critically ill patients receiving enteral nutrition from 8 intensive care units (ICUs) in Australia and New Zealand from May 23, 2022, to August 23, 2023, with final follow-up on November 21, 2023.
INTERVENTION: Two isocaloric enteral formulae were compared: augmented protein (100 g protein/L) vs usual protein (63 g protein/L). ICUs used formulae sequentially for 3 months over a 12-month period; 4 ICUs commenced with augmented protein and 4 commenced with usual protein.
MAIN OUTCOMES AND MEASURES: The primary outcome was the number of days free of admittance to the index hospital and alive at day 90. Secondary outcomes included days free of the index hospital at day 90 in survivors; alive at day 90; durations of invasive ventilation, ICU, and hospital admission; incidences of tracheostomy insertion and new kidney replacement therapy; and hospital discharge destination.
RESULTS: A total of 3397 patients were included (median [IQR] age, 61 (48-71) years; 2157 [64%] male). The median (IQR) number of days free of the index hospital and alive at day 90 was 62 (0-77) days in the augmented protein group and 64 (0-77) days in the usual protein group, with an adjusted-for-period between-group median difference of -1.97 (95% CI, -7.24 to 3.30) days (P = .46). At day 90, a total of 1221 of 1681 patients (72.6%) were alive in the augmented protein group and 1269 of 1716 (74.0%) were alive in the usual protein group (risk ratio, 0.99 [95% CI, 0.95-1.03]). Between-group differences for secondary outcomes included the following: difference in median days free of hospital in survivors, 0.01 (95% CI, -1.94 to 1.96) days; difference in mean duration of invasive ventilation, 6.8 (95% CI, -3.0 to 16.5) hours; cause-specific hazard ratios for durations of ICU admission (time to live ICU discharge), 0.93 (95% CI, 0.88-1.00) and hospital admission (time to live hospital discharge), 0.96 (95% CI, 0.90-1.02); and risk ratio for tracheostomy, 1.15 (95% CI, 0.66-2.01) and new kidney replacement therapy, 0.97 (95% CI, 0.81-1.16). Discharge destinations were similar.
CONCLUSIONS AND RELEVANCE: Augmenting enteral protein during critical illness did not improve number of days free of the index hospital and alive at day 90.
TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12621001484831.
参考来源
- Summers MJ, Chapple LS, Karahalios A, et al. Augmented Enteral Protein During Critical Illness: The TARGET Protein Randomized Clinical Trial. JAMA. 2025. PMID: 40495743. doi:10.1001/jama.2025.9110
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。